GeneDx Holdings Long Term Debt 2020-2025 | WGS
GeneDx Holdings long term debt from 2020 to 2025. Long term debt can be defined as the sum of all long term debt fields.
| GeneDx Holdings Annual Long Term Debt (Millions of US $) |
|
|---|---|
| 2024 | $52 |
| 2023 | $53 |
| 2022 | $6 |
| 2021 | $11 |
| 2020 | $40 |
| 2019 | $0 |
| GeneDx Holdings Quarterly Long Term Debt (Millions of US $) |
|
|---|---|
| 2025-03-31 | $52 |
| 2024-12-31 | $52 |
| 2024-09-30 | $52 |
| 2024-06-30 | $52 |
| 2024-03-31 | $52 |
| 2023-12-31 | $53 |
| 2023-09-30 | $6 |
| 2023-06-30 | $6 |
| 2023-03-31 | $6 |
| 2022-12-31 | $6 |
| 2022-09-30 | $11 |
| 2022-06-30 | $11 |
| 2022-03-31 | $11 |
| 2021-12-31 | $11 |
| 2021-09-30 | $11 |
| 2021-06-30 | |
| 2021-03-31 | |
| 2020-12-31 | |
| 2020-09-30 | |
| 2019-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $1.887B | $0.305B |
| GeneDx Holdings Corp. is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by rare disease data sets. GeneDx Holdings Corp., formerly known as Sema4 Holdings Corp., is based in STAMFORD, Conn. | |||